Special Considerations for Preclinical Testing of Neurological Medical Devices

Preclinical testing for neurological medical devices has unique challenges and considerations during the product development process. There are a variety of medical device types in the neurologic space with numerous target indications including brain/central nervous system, peripheral nerve, and neurovascular devices. The nervous system’s exquisite sensitivity, complex functional networks, and limited regenerative capacity influence the way studies on these devices are designed, executed, and interpreted to meet regulatory acceptance. Whether your product is a neurostimulation implant, regenerative scaffold, neurovascular catheter or stent, a brain-computer interface (BCI), pain management system, neuromonitoring system, or other, the following considerations can help you build a rigorous, efficient, and regulatory compliant preclinical program for your regulatory submission.

Understanding the Complexity of Neurological Systems in Planning Preclinical Research

Neurology devices interact with tissues that govern cognition, movement, sensation, and autonomic function. Unlike many organ systems, neural structures broadly and systemically integrate both anatomical and dynamic functional properties with other organ systems including vascular response, sensory perception, immune response, and homeostasis control. Depending on type, neurologic devices can have an impact on virtually every other organ system including immune, cardiovascular, hormonal, gastrointestinal, renal, or other physiologic functions. When testing a medical device, the therapy impact on the interactions of the neurological system and systemic functions will also need to be evaluated. Depending on the indications for use, device type, and target site for therapeutic use, evaluation of study endpoints for demonstrating the safety and performance of a neurologic device will need to be included in the study design.  

Understanding the efficacy of the device is also an important factor for study consideration. From the outset, most device developers define their device’s mechanism of action in terms of the nervous system mode of action and focus on demonstrating effectiveness of the therapy. This effort helps plan the parameters that need to be measured to demonstrate therapeutic efficacy of the device. Therapeutic efficacy study designs focus on linking device parameters to measurable neural outcomes such as — evoked potentials, local field potentials, conduction velocity, perfusion metrics, neuronal regeneration, and behavior. The understanding of these interactions helps define the parameters that will demonstrate device function during subsequent studies. In many cases physiological response surrogates for showing a therapeutic response can be used throughout the product development study cycle for both efficacy and safety study to demonstrate studies were performed in a manner predictive of clinical use.

Device–Tissue Interactions: Why Neuroanatomy and Implant Strategy Matters

Early on, most neurologic device developers focus on the device indications for use and human clinical target or implant site that will ultimately be used in patients. This effort is a “bench to bedside” approach and “starting with the end in mind” to evaluate key aspects of how the device will ultimately be deployed and used in humans. It will shape what the device looks like, how it is used, and refine the intended clinical purpose of the therapy. Understanding human anatomy and device implantation or deployment is a critical and necessary requirement for moving forward with the final design. This development step often involves reviewing literature, discussions with key opinion leading physicians or end users, human cadaver study with the device, and early evaluations of implantability, usability, and/or critical bench testing requiring human anatomical positioning of the device type. Not only does the intended neurological target matter but also understanding downstream or systemic effects of the therapy will inform studies during device development.

When developing a surgical implantation approach, focus on insertion or implantation techniques that minimize penetration injury and shear forces. Evaluate coatings or surface treatments that potentially could cause friction and/or inflammatory response. Quantify insertion torque, pull-out forces, and motion using benchtop and ex vivo models before in vivo work. For active implants, characterize energy delivery parameters, thermal rise, and electromagnetic fields in situ since the nervous system is susceptible to heat and field-induced changes in excitability. Plan for explant and revision surgery scenarios in your preclinical protocol; removal forces, tissue adherence, and re-insertion feasibility are frequent regulatory questions.

Selecting Appropriate Animal Models for Neurological Medical Devices

Determining the appropriate animal model for device testing early is a key element in setting up a successful regulatory study program. Species choice should be driven by anatomical fidelity, physiological comparability, and the specific questions your device needs to answer. Reviewing the literature and previous experience with similar devices is most often the best place to start when choosing a model. Smaller species such as rabbits or rodents are efficient for early biocompatibility, basic electrophysiology, and behavioral signals, but may not be appropriate for human sized devices that cannot be scaled down. Large animal models, (such as ovine and porcine) offer closer nervous system anatomy, facilitating realistic clinically relevant device use such as interventional delivery, surgical placement, and utilization of the device in use as intended.

In most cases, different endpoints will be evaluated in both small and large species to obtain the entire data set necessary for a complete device evaluation. During product development planning, define a phased approach. For example, for a neurovascular device; use small animals to de-risk materials, coatings, and initial functionality. Transition to large animals for human-scale deployment, imaging, and anchoring assessment. If your device targets intracranial vessels, select models with comparable carotid and cerebral branch patterns. While it is best to avoid disease models, sometimes it is necessary, and in these cases considering disease models that mimic atherosclerosis, aneurysm hemodynamics, or stroke may help demonstrate efficacy and performance. Regardless of the neurological medical device type, thinking through an iterative approach which utilizes appropriate species will help align the overall medical device product development plan. Of highest priority, animal welfare considerations and applying the 3Rs (Replace, Reduce, Refine) with strong justification will need to be considered in study design. Ensuring that only necessary studies are carried out on animals and humane considerations are incorporated is the right thing to do.

Functional and Behavioral Assessments: Beyond Structural Validation

 A key consideration for neurologic devices is demonstration of device intended use effects, as well as evaluation of study subjects for any potential adverse behavioral or physical response that is predictive of questionable device efficacy and/or safety concerns. Regulators and clinicians will look for evidence that your device produces reliable, meaningful changes in neurological performance based on device claims. When planning preclinical studies, link your endpoints to the intended clinical benefit. Try to establish, define, and validate surrogate measurable functional responses that can be predictive of therapeutic efficacy. For motor restoration or modulation for example, evaluation might include gait analysis, rotarod or ladder evaluation, grip strength, or kinematic tracking parameters to quantify improvements or show any negative responses. For sensory devices or nociception modulation, common evaluation includes applying von Frey test, hot plate test, or conditioned place preference paradigms with blinded scoring. For cognitive or cortical interfaces, evaluate task performance and error rates, latency, and signal-to-noise ratio under varying device configurations

For neurostimulation devices, combine behavioral outcomes with objective electrophysiology monitoring. Examples may include evoked potentials, compound muscle action potentials, local field potentials, and Electroencephalogram (EEG) readings to tie behavior to neural circuit changes. For neurostimulation, systematically map dose–response curves across frequency, pulse width, and amplitude, and include safety thresholds for after-discharges or off-target activation to achieve target nerve capture. Map impedance over time for implants to evaluate any inflammatory encapsulation impact on device function. To ensure data acceptability, include controls such as predicate controls, sham surgeries or off-target placements, randomization, and blinding of assessors to address potential bias. Comprehensive neurologic physical exams at key intervals throughout a study supplement the neurobehavioral and physiological evaluations and will help adjudicate any adverse observations. Neurobehavioral assessments also may be necessary for your regulatory submission. Regulatory panels often want to see not only neurobehavioral feasibility of efficacy to establish risk-benefit evaluations of a device to move forward to the clinic, but also impact of the device on these endpoints to ensure the device therapy does not demonstrate adverse events to establish safety of the therapy.

Advanced Imaging Techniques for Neurological Medical Device Testing

The use of imaging in neurologic preclinical studies is often required to demonstrate and interpret device stability and safety. The use of imaging techniques, such as MRI, CT, Fluoroscopy, or Echo (Ultrasound) are often utilized in studies to confirm device placement, implant stability, migration, assess edema, potential hemorrhage, evaluate scarring or inflammatory response, and measure function where applicable. Understanding MRI safety and artifact characterization, determining RF-induced heating, displacement forces, and image distortion can help inform material choices and device tolerances. CT, fluoroscopy and similar radiographic visualization help establish hardware position, tissue morphology and inflammatory reactivity, and confirm radio-opaque components. Angiography assesses device patency and function, flow diversion, and thrombosis risk in neurovascular devices. Ultrasound can be used for implantation delivery guidance and to evaluate hemodynamics. Intravascular OCT and IVUS can verify endothelial coverage and neointimal formation in neurovascular implants. These are just a few examples of how advanced macroscopic imaging may be employed during preclinical neurologic studies.

Microscopic optical modalities will generally also be a necessary part of a neurologic device evaluation. Histopathology evaluation of tissue response to implanted devices is required in nearly every GLP safety and performance study. Focus is on neurotoxicity of the devices, tissue response to the device, and any down-stream or systemic reaction. Multiple histology stains targeted to evaluating nerve tissues are often required for such things as axon counts, Schwann cell response, and myelin integrity. Other more detailed microscopic evaluations may also be necessary. Specialized microscopy such as confocal two-photon microscopy, and electron microscopy may also be required to further characterize pathologies and device tissue responses such as microglial and astrocyte responses, axon integrity, or other nerve response of neurological devices when further detail is required.

Aligning the imaging schedule with key biological response milestones should be considered when designing the study. Example timing considerations might include immediate post-implant verification, subacute inflammation windows (1–4 weeks), and sub chronic and chronic integration and resolution (8–26+ weeks). Choice of timing will depend on device type and expected characteristics to be evaluated. It is important to ensure comprehensive comparative data evaluation between imaging data, histopathology, in-life health, clinical pathology, and neurobehavioral responses. Ensuring each evaluation takes into consideration other endpoint results will ensure alignment of the data and mitigate regulatory questions following a submission.

Regulatory Expectations for Neurological Medical Devices: Preclinical Perspective

Regulatory reviewers expect complete, coherent packages that address safety, performance, and risk. Plan your program against recognized standards and guidance documents. For biocompatibility, follow ISO 10993, including chemical characterization, cytotoxicity, sensitization, irritation, systemic toxicity, and local tissue effects appropriate to duration and contact. Incorporating ASTM 2901-19, Standard Guide for Selecting Tests to Evaluate Potential Neurotoxicity of Medical Devices, is often required by regulators to include applicable endpoints suggested by this guidance. For your device, be sure to include review of applicable regulations and any special controls for certain neurological devices (21 CFR 882). It will assist in determining device classification and ensure critical requirements are not missed. It is also important to review previous public information related to predicate device submissions to help understand what others have done in the past. A comprehensive regulatory assessment of the device is highly recommended early in the planning phase and will help ensure a good roadmap for all necessary studies and data required for the regulatory submission for the device. Once a roadmap of testing has been laid out, seek validation of study plans by the FDA through the Pre-sub process to ensure critical device evaluations needed for regulatory approval are not forgotten.

• Active Implants and Electrical Safety: Design to applicable standards (such as IEC and ISO). Consider evaluating usability in preclinical procedures where human factors can help predict surgical or clinical workflow and potentially device safety.
• MRI Compatibility: If your device is planned to be used or scanned in MRI environments, incorporate ASTM standards for MR safety and compatibility (e.g., heating, torque, displacement, and artifact assessments) and be prepared to support MR conditional labeling with robust in vivo and bench data.
• Neuromodulation and BCI Devices: Ensure you address stimulation safety, charge density limits, electrode corrosion, hermeticity, telemetry reliability, and cybersecurity where applicable. Evaluate the device function during in-life preclinical studies to ensure tissue response (example: impedance due to inflammation, device removal feasibility, and subsequent tissue healing when applicable).

As previously mentioned, engage early with regulators via pre-submission meetings to align on endpoints, model selection, and study durations, and to identify any device-specific guidance applicable to your category. A preclinical neurology CRO experienced with submissions for neurological medical devices can streamline this alignment and anticipate common review questions.

Mitigating Risk Through Robust Preclinical Study Design

Depending on clinical risk and device categorization, every new medical device will likely require a series of tests to inform the overall safety and performance of the device before clinical use. For animal studies that may be required, a great place to start is reviewing the FDA guidance: General considerations for animal studies intended to evaluate medical devices, Guidance for industry and food and drug staff, March 28, 2023. Select primary and secondary endpoints that capture both safety and performance, and power your study appropriately to detect meaningful data. Use randomization and blinding to prevent bias whenever possible. Consider incorporating device usability into the protocol: deployment steps, potential use error modes, required training, procedural time, and user feedback are helpful as these factors often drive clinical adoption and safety, and can be used to refine device design. Select study duration based on the intended use of the device (acute vs. chronic). This will ensure appropriate endpoints are evaluated compatible with the intended use.

Control confounding and variability at every stage in a study. Be aware that anesthesia is often required in animal studies, but it can impact neurologic response and neurophysiology, giving misleading results. Because animal anatomy can differ from intended human target implant sites, be sure to define surgical landmarks and device placement tolerances and use intraoperative imaging or navigation to verify accuracy. It is ideal to confirm placement of devices through surrogate physiological response if applicable to demonstrate device function. Ensuring device function throughout a study is key to interpretation, so evaluation should include implant movements, impedance or electrical parameter or other device applicable functional changes, and perioperative or in-life complications. When developing the product, use a staged approach with clear go/no-go criteria between phases to de-risk expensive large-animal or GLP work.

How Specialized Preclinical Neurology CRO Support Accelerates Success

The fastest path to high-quality data is a coordinated team that understands neurology, neurophysiology, complex surgery, advanced imaging, electrophysiology, comparative medicine, clinical risk-benefit considerations, and regulatory expectations. Experienced preclinical partners can help you refine indications for use, select models that match your claims, and build integrated testing protocols that combine behavior, imaging, neural response measurements, device tissue response and pathology, biocompatibility endpoints, evaluation and adjudication of potential adverse events, and optimize success criteria for the study. They can provide access to necessary technology such as navigation systems, imaging suites, angiography labs, telemetry platforms, and chronic housing conditions compatible with long-term neural monitoring. An expert preclinical neurology CRO most importantly, will help anticipate regulatory questions and structure your studies to preempt them. They’ll ensure GLP compliance where needed, institute rigorous data governance, and deliver study reports that support submissions for neurological medical devices. They can help you make smart trade-offs such as balancing study duration against milestone pressures and regulatory goals, and how to design protocols that preserve optionality across multiple clinical indications for future product considerations.